Tumor markers and neutrophil-lymphocyte ratio’s predictive role in endometriosis
article
OA: diamond
CC0
Abstract
Objective: Endometriosis is characterized by the development of endometrial tissue outside the uterine cavity. Aim of this study is to investigate the diagnostic value of neutrophil/lymphocyte ratio (NLR) and cancer antigen (CA)-125 in a diagnosis of endometriosis. Material and methods: In this retrospective study, the medical data of a total of 30 patients who underwent surgery due to endometriosis between January 2012 to December 2017 at Pamukkale University were analyzed. Results: NLR and CA-125 were increased in the patients with endometriosis. Conclusion: A diagnostic test without the need for surgery will reduce the associated surgical risks, increase accessibility to a diagnostic test and improve treatment outcomes.
My notes (saved in your browser only)
Condition tags
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (10)
- Blood biomarkers for the non-invasive diagnosis of endometriosis via openalex
- Diagnostic value of the neutrophil-to-lymphocyte ratio and the combination of serum CA-125 for stages III and IV endometriosis via openalex
- Endometriosis via openalex
- Endometriosis: epidemiology and aetiological factors via openalex
- New insights into the pathophysiology of endometriosis: from chronic inflammation to danger signal via openalex
- Peripheral biomarkers of endometriosis: a systematic review via openalex
- Update on Biomarkers for the Detection of Endometriosis via openalex
- W2158516834 via openalex
- W2283760758 via openalex
- W4211081176 via openalex
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0
· commercial use OK